Published: Sun, October 18, 2020
Medical | By

Coronavirus vaccine deployment in UK could happen by New Year

Coronavirus vaccine deployment in UK could happen by New Year

Russian Federation registered the new vaccine in August, before a large-scale Phase-3 clinical trial was conducted.

Raab told Sky News "Anyone basically trying to sabotage the efforts of those trying to develop a vaccine is deeply reprehensible and it's pretty unacceptable and unjustified in any circumstances".

Last month, Kirill Dmitriev, CEO, RDIF informed that Russian Federation is in close dialogue with the Indian government and drug manufacturers of India regarding localization of production of its Sputnik V vaccine in India.

SputnikV, a vaccine against coronavirus, has been developed by the Gamaleya National Research Center of Epidemiology and Microbiology and the RDIF.

The study also revealed that the USA, the United Kingdom and India are the top three nations with a geometric mean of 3.27 per cent, 3.59 per cent, and 5.39 per cent, respectively, of mutation similarity score with other 72 countries.

According to sources, it would be multi-centre, observer-blind, randomised controlled study.

An expert panel at the Central Drugs Standard Control Organisation (CDSCO) on Friday recommended granting permission to Dr Reddy's Laboratories for conducting phase 2 clinical trials of the Russian Covid-19 vaccine, Sputnik V, in India, sources said.

The Russian Direct Investment Fund had also said that the deliveries could potentially begin in late 2020 subject to completion of successful trials and registration of the vaccine by regulatory authorities in India. RDIF, which is marketing the Sputnik V, will supply 100 million doses to Dr Reddy's.

It is now completing phase 3 of clinical trials in Russian Federation as per the WHO's protocols. Additionally, phase 3 clinical trial of the vaccine has commenced in the UAE last week, the release on Saturday said.

In addition, the RDIF, together with its partners, is conducting Sputnik V clinical trials in Belarus, the United Arab Emirates, and Venezuela.

In light of concerns raised by lower-income countries, the WHO, Gavi vaccine alliance, and Coalition for Epidemic Preparedness Innovations established the COVID-19 Vaccine Global Access Facility (COVAX) that aims to ensure the fair distribution of safe and effective vaccines against the disease. India is cooperating in vaccine development with five pharma companies, including AstraZeneca and Novavax.

Like this: